Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 80

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Neurofibromatosis

Recruiting

Imaging Study with 89Zr-Bevacizumab for Predicting Treatment Effects in Patients with NF2-Related Schwannomatosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab Zirconium Zr-89
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Neoplasm malignant

Recruiting

Study of Lower Dose Olaparib Combined with Cobicistat to Improve Treatment Tolerance in Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cobicistat
  • Sponsor:Stichting Radboud University Medical Center

Ovarian cancer

Recruiting

Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Arcagy Gineco

Rectal cancer

Recruiting

Evaluating SGM-101 (fluorochrome-labeled antibody) in patients with locally advanced or recurrent rectal cancer undergoing surgery

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Chimeric Monoclonal Antibody Against Carcinoembryonic Antigen Conjugated To Fluorochrome Bm-104
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Alisertib with Hormone Therapy for Patients with HR+, HER2- Recurrent or Metastatic Breast Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alisertib Sodium
  • Sponsor:Puma Biotechnology Inc.

Metastatic neoplasm

Recruiting

Evaluation of drug combination therapy (olaparib, nilotinib, tremelimumab, and durvalumab) for patients with advanced or metastatic solid tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Centre Leon Berard

Neoplasm malignant

Recruiting

Study on Atezolizumab, Amivantamab, and Futibatinib for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Vall D Hebron Institute Of Oncology

Malignant glioma

Recruiting

Study on Bortezomib and Temozolomide for Patients with Recurrent Grade IV Glioma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Helse Bergen HF

Oesophageal carcinoma+3

Recruiting

Study on Changes in [18F]F-AraG Uptake After Radiotherapy in Patients with Non-Small Cell Lung Cancer, Melanoma, Breast Cancer, and Esophageal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nelarabine
  • Sponsor:Amsterdam UMC Stichting

Pancreatic carcinoma+1

Recruiting

Study on PBP1510 and Gemcitabine for Patients with Advanced Pancreatic Cancer After Previous Chemotherapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anti-(Pancreatic Adenocarcinoma Upregulated Factor) Igg1 Humanised Monoclonal Antibody
  • Sponsor:Prestige Biopharma Ltd

Non-small cell lung cancer stage III+3

Recruiting

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.